Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
Shai Shimony(Tel Aviv University), Marlise R. Luskin(Harvard University), Andrew E. Place(Dana-Farber Cancer Institute), Jonathan Paolino(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Lewis B. Silverman(Boston Children's Hospital), Lachelle D. Weeks(Harvard University), Lynda M. Vrooman(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Richard M. Stone(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Yannis K. Valtis(Brigham and Women's Hospital), Donna Neuberg(Otsuka (Japan)), Yiwen Liu(Sun Yat-sen University), Andrew M. Brunner(Massachusetts General Hospital)
Cited by 40
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
|Nature Medicine|2020|1k
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
|Journal of Clinical Oncology|2001|825